Challenges to global drug submissions and approvals - an industry perspective
This article was originally published in SRA
Max Wegner considers some of the hurdles to running a global drug development programme.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.